Clinical Trial Update: A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy [Phase 4]

View source ↗

Summary

A randomized, controlled Phase 4 trial evaluating rituximab for treatment of IgA nephropathy is underway, with status not specified.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: XIEJINGYUAN | Conditions: IgA Nephropathy | Phase 4 | Status: UNKNOWN